Brief: Protalix BioTherapeutics Q2 net income USD -2.203 million
14/08/2024 12:00
Aug 14 (Reuters) - Protalix BioTherapeutics Q2 operating income USD -2.427 million. * Q2 net income USD -2.203 million * Q2 EPS USD -0.03
Recent news on Protalix BioTherapeutics
See all newsIsrael's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Israel's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio